Abilify Maintena

Abilify Maintena®

(aripiprazole)

19 Aug, 2024

Switching from an oral to a long-acting injectable in an acute setting or transitioning to community care

Professors John Kane, Philip Gorwood and David Castle discuss the issues facing physicians in the acute setting and provide advice on switching patients with schizophrenia to a long-acting injectable.

Box

Body

Abilify Maintena PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia.
This product is not listed on the PBS for the treatment of bipolar 1 disorder.
text

Body

Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

Abilify Maintena PI

Abilify Maintena is a registered trademark of Otsuka Pharmaceutical Co., Ltd. Abilify Maintena is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.

Contributor

Professor David Castle

Professor of Psychiatry, Centre for Mental Health Services Innovation, The University of Tasmania, Hobart

Professor John Kane

Senior Vice President of Behavioural Health Services, Northwell Health and Chair of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Professor Philip Gorwood

Professor of Psychiatry at Sainte-Anne Hospital and affiliated with the University of Paris